SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Video navigation menu

EMPA-REG Outcome - the first CV endpoint trial of SGLT2-inhibition 0:18
Effect of empagliflozin on HbA1c, BP, weight and hematocrit 3:46
The reduction in the 3-point MACE with empagliflozin vs. placebo is mainly driven by reduced CV mortality 4:40
Heart failure outcomes with empagliflozin in EMPA-REG Outcome 7:21
Outcomes in patients with heart failure at baseline 9:09
Adverse events in EMPA-REG Outcome 11:21
Overall clinical benefit of empagliflozin 11:58

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.